Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035) Journal Article
| Authors: | Lee, E. K.; Tan-Wasielewski, Z.; Aghajanian, C.; Coleman, R. L.; Curtis, J.; Hirsch, M. S.; Matulonis, U. A.; Cantley, L. C.; Mills, G. B.; Doyle, L. A.; Liu, J. F. |
| Article Title: | Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035) |
| Abstract: | Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss. © 2020 The Authors |
| Keywords: | pten; pi3k/akt pathway; platinum resistant ovarian cancer; mk-2206; akt inhibitor; serous ovarian carcinoma |
| Journal Title: | Gynecologic Oncology Reports |
| Volume: | 32 |
| ISSN: | 2352-5789 |
| Publisher: | Elsevier B.V. |
| Date Published: | 2020-05-01 |
| Start Page: | 100546 |
| Language: | English |
| DOI: | 10.1016/j.gore.2020.100546 |
| PROVIDER: | scopus |
| PMCID: | PMC7021536 |
| PUBMED: | 32083163 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 March 2020 -- Source: Scopus |
